Let's get seerious: More accurate staging with consequent high management impact is not just stage migration

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages 819-

  Hofman, Michael S ^a   Ball, David L ^a   Mac Manus, Michael P ^a   Ware, Robert ^a   Hicks, Rodney J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; HEALTH CARE PLANNING; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84875747195     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.5872     Document Type: Letter

References (4)

1. Dinan MA, Curtis LH, Carpenter WR, et al: Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among Medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol 30:2725-2730, 2012
2. Hicks RJ, Kalff V, MacManus MP, et al: (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 42:1596-1604, 2001 (Pubitemid 33131317)
3. Kalff V, Hicks RJ, MacManus MP, et al: Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study. J Clin Oncol 19:111-118, 2001 (Pubitemid 32063487)
4. Gregory DL, Hicks RJ, Hogg A, et al: Effect of PET/CT on management of patients with non-small cell lung cancer: Results of a prospective study with 5-year survival data. J Nucl Med 53:1007-1015, 2012